Logo image of ARAV

Aravive Inc (ARAV) Stock Fundamental Analysis

NASDAQ:ARAV - Nasdaq - US03890D1081 - Common Stock - Currency: USD

0.0401  -0.01 (-13.39%)

After market: 0.042 +0 (+4.74%)

Fundamental Rating

2

Taking everything into account, ARAV scores 2 out of 10 in our fundamental rating. ARAV was compared to 571 industry peers in the Biotechnology industry. The financial health of ARAV is average, but there are quite some concerns on its profitability. ARAV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ARAV has reported negative net income.
In the past year ARAV has reported a negative cash flow from operations.
In the past 5 years ARAV always reported negative net income.
In the past 5 years ARAV always reported negative operating cash flow.
ARAV Yearly Net Income VS EBIT VS OCF VS FCFARAV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -306.54%, ARAV is not doing good in the industry: 96.29% of the companies in the same industry are doing better.
ARAV has a Return On Equity of -2344.12%. This is amonst the worse of the industry: ARAV underperforms 86.85% of its industry peers.
Industry RankSector Rank
ROA -306.54%
ROE -2344.12%
ROIC N/A
ROA(3y)-75.18%
ROA(5y)-71.51%
ROE(3y)-289.85%
ROE(5y)-204.67%
ROIC(3y)N/A
ROIC(5y)N/A
ARAV Yearly ROA, ROE, ROICARAV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARAV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARAV Yearly Profit, Operating, Gross MarginsARAV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

ARAV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARAV has more shares outstanding
There is no outstanding debt for ARAV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARAV Yearly Shares OutstandingARAV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
ARAV Yearly Total Debt VS Total AssetsARAV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

ARAV has an Altman-Z score of -81.87. This is a bad value and indicates that ARAV is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ARAV (-81.87) is worse than 98.99% of its industry peers.
ARAV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -81.87
ROIC/WACCN/A
WACC10.5%
ARAV Yearly LT Debt VS Equity VS FCFARAV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M 150M

2.3 Liquidity

ARAV has a Current Ratio of 0.98. This is a bad value and indicates that ARAV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.98, ARAV is not doing good in the industry: 90.56% of the companies in the same industry are doing better.
ARAV has a Quick Ratio of 0.98. This is a bad value and indicates that ARAV is not financially healthy enough and could expect problems in meeting its short term obligations.
ARAV has a worse Quick ratio (0.98) than 89.38% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.98
ARAV Yearly Current Assets VS Current LiabilitesARAV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

ARAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.32%, which is quite impressive.
ARAV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.28%.
Measured over the past years, ARAV shows a very negative growth in Revenue. The Revenue has been decreasing by -25.56% on average per year.
EPS 1Y (TTM)59.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%154.9%
Revenue 1Y (TTM)-19.28%
Revenue growth 3Y24.38%
Revenue growth 5Y-25.56%
Sales Q2Q%-44.35%

3.2 Future

Based on estimates for the next years, ARAV will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.50% on average per year.
Based on estimates for the next years, ARAV will show a very negative growth in Revenue. The Revenue will decrease by -21.62% on average per year.
EPS Next Y90.73%
EPS Next 2Y39.94%
EPS Next 3Y25.99%
EPS Next 5Y10.5%
Revenue Next Year-38.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-21.62%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ARAV Yearly Revenue VS EstimatesARAV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0 0 0 0
ARAV Yearly EPS VS EstimatesARAV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ARAV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARAV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARAV Price Earnings VS Forward Price EarningsARAV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARAV Per share dataARAV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

ARAV's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.94%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARAV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Aravive Inc

NASDAQ:ARAV (1/26/2024, 8:02:10 PM)

After market: 0.042 +0 (+4.74%)

0.0401

-0.01 (-13.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/amc
Earnings (Next)03-13 2024-03-13/amc
Inst Owners0.01%
Inst Owner Change0.27%
Ins Owners5.52%
Ins Owner Change0%
Market Cap2.95M
Analysts43.33
Price Target0.26 (548.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)210.2%
Min EPS beat(2)58.96%
Max EPS beat(2)361.44%
EPS beat(4)2
Avg EPS beat(4)66.57%
Min EPS beat(4)-103.8%
Max EPS beat(4)361.44%
EPS beat(8)3
Avg EPS beat(8)34.04%
EPS beat(12)6
Avg EPS beat(12)27.35%
EPS beat(16)8
Avg EPS beat(16)14.94%
Revenue beat(2)2
Avg Revenue beat(2)584.84%
Min Revenue beat(2)187.33%
Max Revenue beat(2)982.35%
Revenue beat(4)4
Avg Revenue beat(4)384.65%
Min Revenue beat(4)125.18%
Max Revenue beat(4)982.35%
Revenue beat(8)7
Avg Revenue beat(8)250.15%
Revenue beat(12)10
Avg Revenue beat(12)281.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.08%
EPS NY rev (1m)0%
EPS NY rev (3m)67.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)57.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.1
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -306.54%
ROE -2344.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.18%
ROA(5y)-71.51%
ROE(3y)-289.85%
ROE(5y)-204.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.98
Altman-Z -81.87
F-Score3
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%154.9%
EPS Next Y90.73%
EPS Next 2Y39.94%
EPS Next 3Y25.99%
EPS Next 5Y10.5%
Revenue 1Y (TTM)-19.28%
Revenue growth 3Y24.38%
Revenue growth 5Y-25.56%
Sales Q2Q%-44.35%
Revenue Next Year-38.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-21.62%
EBIT growth 1Y8.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.95%
EBIT Next 3Y2.34%
EBIT Next 5Y-6.26%
FCF growth 1Y-203.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-203.21%
OCF growth 3YN/A
OCF growth 5YN/A